CombiGene’s Collaboration And Licensing Agreement With Spark Therapeutics

VISCHER advised CombiGene on the deal.

CombiGene AB and Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced the signing of an exclusive collaboration and licensing agreement for CombiGene’s CG01 project, a gene therapy which aims to treat drug resistant focal epilepsy.

The agreement provides Spark with the exclusive worldwide license to develop, manufacture and commercialize CG01. CombiGene will continue to execute certain aspects of the preclinical program in collaboration with Spark. Under the terms of agreement, CombiGene is eligible to receive up to USD 328.5m excluding royalties, with USD 8.5m upon signing, up to USD 50m at preclinical and clinical milestones. CombiGene will also be reimbursed for certain authorized R&D expenses. Upon commercialization, CombiGene is eligible for tiered royalties ranging from the mid-single digits up to low double-digits based on net sales.

Spark Therapeutics, Inc. is a developer of gene therapy treatments, which treat debilitating genetic diseases.

Combigene AB specializes in gene therapy for neurological diseases. The Company particularly focuses treatments for the prevention epileptic seizures.

The Vischer team was led by Dr. Stefan Kohler (Picture).

Involved fees earner: Stefan Kohler – VISCHER AG;

Law Firms: VISCHER AG;

Clients: CombiGene AB;

Author: Federica Tiefenthaler